{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:30:46Z","timestamp":1783621846623,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to evaluate the risk of adverse events associated with chloroquine (CQ) and hydroxychloroquine (HCQ) in patients with systemic lupus erythematosus (SLE), using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Disproportionality analysis was conducted using the Reporting Odds Ratio (ROR) to detect potential safety signals. Sensitivity analyses were performed to validate these signals, and the time to onset for each Preferred Term (PT) was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2004 and 2024, a total of 2,575 adverse event reports related to HCQ or CQ use in patients with SLE were identified in the FAERS database, of which 437 involved ocular adverse events. The most frequently reported ocular conditions were cataract, macular degeneration, and glaucoma. Disproportionality analysis demonstrated strong associations between HCQ\/CQ use and retinal degeneration (ROR = 28.5, 95%CI: 19.94\u201340.74), cystoid macular oedema (ROR = 12.46, 95%CI: 8.01\u201319.37), and optic atrophy (ROR = 6.55, 95%CI: 3.51\u201312.19). Sensitivity analyses, conducted after excluding SLE cases, indicated that all but one event (vitreous floaters) remained statistically significant, suggesting that these risks are more likely attributable to HCQ\/CQ exposure than to the underlying disease. The time-to-onset analysis showed that cataract had the shortest average onset time (125.5\u00a0days), whereas retinal degeneration had the longest (937.5\u00a0days).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The extensive clinical use of HCQ and CQ raises significant concerns regarding their ocular safety profile. This study provides real-world pharmacovigilance evidence supporting a substantial risk of ocular adverse events associated with HCQ\/CQ use. Further mechanistic and prospective studies are warranted to elucidate the underlying pathophysiological pathways and to confirm these associations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1498814","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:26:22Z","timestamp":1751261182000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/archopht.1964.00970010254019","article-title":"The pathology of chloroquine retinopathy","volume":"71","author":"Bernstein","year":"1964","journal-title":"Arch. Ophthalmol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"A277","DOI":"10.1016\/j.autrev.2009.12.008","article-title":"The geoepidemiology of systemic lupus erythematosus","volume":"9","author":"Borchers","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/2045-3701-1-10","article-title":"Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration","volume":"1","author":"Chen","year":"2011","journal-title":"Cell. Biosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12016-015-8469-8","article-title":"A critical review of the effects of hydroxychloroquine and chloroquine on the eye","volume":"49","author":"Costedoat-Chalumeau","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10238-017-0479-9","article-title":"Systemic lupus erythematosus and ocular involvement: an overview","volume":"18","author":"Dammacco","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12886-020-01360-w","article-title":"Risks of ophthalmic disorders in patients with systemic lupus erythematosus - a secondary cohort analysis of population-based claims data","volume":"20","author":"Hsu","year":"2020","journal-title":"BMC Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.seizure.2022.01.011","article-title":"Eye disorders associated with newer antiepileptic drugs: a real-world disproportionality analysis of FDA adverse event reporting system","volume":"96","author":"Hu","year":"2022","journal-title":"Seizure"},{"key":"B9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy - implications of research advances for rheumatology care","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-025-00856-9","article-title":"Drug-related macular edema: a real-world FDA adverse event reporting system database study","volume":"26","author":"Li","year":"","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"13407","DOI":"10.1038\/s41598-025-92796-x","article-title":"Real-world pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database","volume":"15","author":"Li","year":"","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1498191","DOI":"10.3389\/fphar.2025.1498191","article-title":"Real-world pharmacovigilance analysis of drug-related cataracts using the FDA adverse event reporting system database","volume":"16","author":"Li","year":"","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","article-title":"Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database","volume":"111","author":"Liu","year":"2025","journal-title":"Int. J. Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1378010","DOI":"10.3389\/fphar.2024.1378010","article-title":"Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database","volume":"15","author":"Long","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Luo","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/17512433.2023.2294002","article-title":"Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database","volume":"17","author":"Mao","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1056\/NEJMra1105239","article-title":"Genomics of cardiovascular disease","volume":"365","author":"O\u2019Donnell","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/acr.24572","article-title":"Predictors of initial hydroxychloroquine receipt among medicaid beneficiaries with incident systemic lupus erythematosus","volume":"74","author":"Pryor","year":"2022","journal-title":"Arthritis Care Res. Hob."},{"key":"B20","first-page":"1158","article-title":"Chloroquine retinopathy in the rhesus monkey","volume":"17","author":"Rosenthal","year":"1978","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/tvst.12.7.6","article-title":"Deep learning algorithm detects presence of disorganization of retinal inner layers (DRIL)-an early imaging biomarker in diabetic retinopathy","volume":"12","author":"Singh","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archopht.1964.00970010098016","article-title":"Histopathology of chloroquine retinal toxicity","volume":"71","author":"Wetterholm","year":"1964","journal-title":"Arch. Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1038\/s41598-023-32297-x","article-title":"Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1498814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:26:22Z","timestamp":1751261182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1498814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":24,"alternative-id":["10.3389\/fphar.2025.1498814"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1498814","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"1498814"}}